Loading
Latest filing published 16 Oct 2026 for Akari Therapeutics Plc, €7.
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Abizer Gaslightwala appears in our data through filings on Akari Therapeutics PLC shares, published by SEC (Form 4). Between 26 December 2024 and 14 October 2026, the trades on record add up to 19 filings.
Every open-market trade on record is a purchase: 7 purchases worth €49k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 10 share grants and 2 option exercises.
Half of the purchases are above €6,407 and half below. The 7 purchases reviewed show no overlap with other insiders buying the same stock within a month. Ninety days after publication, 4 purchases show a median change of -30.3%, with the price up in 0% of them. They describe history only and say nothing certain about the share price ahead.
On 16 October 2026 came the latest disclosure, an option exercise for €7 in Akari Therapeutics PLC. The last insider purchase was made public on 29 August 2025, 420 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations